We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Estrogen Receptor Genotypes, Menopausal Status, and the Lipid Effects of Tamoxifen.
- Authors
Ntukidem, N. I.; Nguyen, A. T.; Stearns, V.; Rehman, M.; Schott, A.; Skaar, T.; Jin, Y.; Blanche, P.; Li, L.; Lemler, S.; Hayden, J.; Krauss, R. M.; Desta, Z.; Flockhart, D. A.; Hayes, D. F.
- Abstract
Tamoxifen induces important changes in serum lipid profiles in some women; however, little information is available to predict which women will experience improved lipid profiles during tamoxifen therapy. As part of a multicenter prospective observational trial in 176 breast cancer patients, we tested the hypothesis that tamoxifen-induced lipid changes were associated with genetic variants in candidate target genes (CYP2D6, ESR1, and ESR2). Tamoxifen lowered low-density lipoprotein cholesterol (P<0.0001) by 23.5 mg/dl (13.5–33.5 mg/dl) and increased triglycerides (P=0.006). In postmenopausal women, the ESR1-XbaI and ESR2-02 genotypes were associated with tamoxifen-induced changes in total cholesterol (P=0.03; GG vs GA/AA) and triglycerides (P=0.01; gene–dose effect), respectively. In premenopausal women, the ESR1-XbaI genotypes were associated with tamoxifen-induced changes in triglycerides (P=0.002; gene–dose effect) and high-density lipoprotein (P=0.004; gene–dose effect). Our results suggest that estrogen receptor genotyping may be useful in predicting which women would benefit more from tamoxifen.Clinical Pharmacology & Therapeutics (2008); 83, 5, 702–710. doi:10.1038/sj.clpt.6100343
- Subjects
TAMOXIFEN; MENOPAUSE; BLOOD lipids; GENOTYPE-environment interaction; THERAPEUTICS; PHYSIOLOGY
- Publication
Clinical Pharmacology & Therapeutics, 2008, Vol 83, Issue 5, p702
- ISSN
0009-9236
- Publication type
Article
- DOI
10.1038/sj.clpt.6100343